Market Analysis - Annual Report -April, 2020- Sulfamonomethoxine Sodium
Analyst : Steven
1.Overview of the Current Market Situation
In April 2020, the price of sulfamethoxine sodium generally remained stable, as follows
1.On the supply side, Henan Houyi Pharmaceutical Co.,Ltd. mainly delivered pre-orders in April. Domestic and foreign trade orders have been delivered one after another, and it is expected that the supply shortage will be eased in mid-May. The other two factorys, Jiangsu Tianhe Pharmaceutical Co.,Ltd. and Wujiang Bolin Industry Co.,Ltd. These price is higher than Houyi Pharmaceutical Co.,Ltd., and the delivery time is about one week.
2.On the market demand side, sulfamethoxine sodium is the main market in Vietnam,the weakening of demand in April was mainly due to the fact that most orders were in February and March. At present, customers in the Vietnamese market are mainly waiting for delivery.
3.The upstream supply of sulfamethoxine sodium is currently stable and there is no possibility of rising again.

2.Market Forecast for Next Month
In summary, it is expected that in May 2020, production and delivery at the factory will gradually become normal, the market has a large right to speak, and the factory has a small right to speak. The price is stable in May.
| Factor |
Explanation |
| Inventory |
Henan Houyi Pharmaceutical Co.,Ltd. currently does not have any inventory, and mainly focuses on pre-delivery orders. Jiangsu Tianhe Pharmaceutical Co.,Ltd. and Wujiang Bolin Industry Co.,Ltd. deliver fast. |
| Market Demand |
The market demand is small, mainly affected by the epidemic and the purchase period of customers is concentrated in February and march. |
|
Factory Mentality |
Henan Houyi Pharmaceutical Co.,Ltd. currently has the best price and high cost performance. Currently Henan Houyi Pharmaceutical Co.,Ltd. is still executing pre-orders. It is expected to be available from stock in mid-May. |
| Upstream Raw Materials |
Currently, the upstream raw material supply is stable. In the short term, the price of API does not have the possibility of a substantial increase. |
2026-10-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
China’s 15th Five-Year Plan Sets New Priorities for Pharmaceutical Innovation and Supply Chains
-
Evonik Expands Slovakian Fermas Site with €80 Million Investment to Boost Pharmaceutical CDMO Capacity
-
India's PV Community Comes Together at the 6th Edition Drug Safety Symposium 2026 – India Chapter to Shape the Future of Patient Safety
-
The project of fine chemicals with 4000 t/a Tebuconazole and Diflufenican is to be built
-
Pharmaconex 2022
-
CPHI Korea 2022
-
Shandong Pharmaceutical Companies Grab Over $1 Billion of Antithrombotic Drugs for The First Imitation, Original Research Drugs Soared 5527%
-
ECHEMI International Trade Business School Bangladesh Pharmaceutical Summary
-
Industrialization Progress of genetically modified pharmaceutical products
-
2022 Top 50 Global Pharmaceutical Companies Released! Pfizer Returns to NO.1, Kexing Counterattack First on the List
Recommend Reading
-
Middle East Crude Exports Rebound Sharply in September as Saudi Arabia Returns to Market at 5.4 Million bpd
-
UAE Breaks Ground on World’s First Gigascale Round-the-Clock Renewable Energy Project, Setting a New Global Standard For Clean Energy
-
Saudi Aramco’s 400,000 bpd Jazan Refinery Shuts After Attack
-
Kraton Announces Strategic Plan to Streamline Polymer Operations in Berre, France
-
LG Chem Enters Semiconductor Stripper Market for the First Time, Cutting Process Time by 50%
-
October China Urea Market First Depressed Then Improved
-
Weak demand leads to a fluctuating decline in phthalic anhydride prices this week in China
-
Weak Demand Weighs on Butadiene Market
-
International oil prices fall from high levels, polybutadiene rubber market weakens
-
Supply and Demand Bearish, Toluene Market Declines